CiNTL
CiNTL.AI is a Netherlands-based AI consultancy offering an integrated AI, ML, and GenAI platform that accelerates clinical trials for pharmaceutical and biotechnology enterprises from its Hilversum headquarters.
- Company typePrivate
- Founded2008
- HeadquartersHilversum, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What CiNTL does
CiNTL.AI is a Netherlands-based consultancy that operates an integrated AI, ML, and GenAI platform aimed at accelerating clinical trials for pharmaceutical and biotechnology enterprises. Founded in 2008 and headquartered in Hilversum, the company is privately held, employs 11-50 people, and presents itself as a vertical specialist addressing slow clinical trial processes, inefficient data analysis, and delayed decision-making in drug development.
The core product, branded as the CiNTL.AI Platform, combines generative AI for producing and processing clinical trial documentation, reports, and analysis with predictive analytics applied to clinical trial data for decision support. AI modalities are restricted to text. The platform is delivered through a direct online enterprise portal (with a login on the company website) targeting pharmaceutical and biotech buyers globally, though no operating geographies, named customers, or case studies are disclosed in the available material.
The business model is opaque. CiNTL.AI does not publicly disclose pricing, contract structures, revenue, funding, ownership composition, or management team details. Marketing presence is limited to organic social channels (Twitter, LinkedIn, and a Facebook-linked contact email). No certifications, regulatory clearances, partnerships, patents, or awards are disclosed, and revenue mechanics are not derivable from the inputs.
CiNTL firmographics
Firmographics- Name
- CiNTL
- Legal name
- CiNTL.AI
- Website
- https://cintl-pm.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CiNTL.AI is a Netherlands-based AI consultancy offering an integrated AI, ML, and GenAI platform that accelerates clinical trials for pharmaceutical and biotechnology enterprises from its Hilversum headquarters.
- Ownership category
- akta.pro rank
CiNTL industry classification
Industry- Product category
- Clinical Trial AI Software
- NAICS
- Custom Computer Programming Services (541511), Software Publishers (5132)
- SIC
- Services-Computer Programming Services (7371), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA), AI Application Enablement Platforms (Copilot/Agent Frameworks, SDKs) (HDAEANAJ)
Keywords
Where CiNTL is headquartered
LocationHeadquarters
- HQ city
- Hilversum
- HQ country
- Netherlands
- HQ region
- Europe
Markets served
CiNTL business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Distribution channels1 record
Marketing channels3 records
CiNTL product offering
Product offeringCore offering
CiNTL.AI provides an integrated AI, ML, and GenAI platform built specifically for pharmaceutical and biotechnology companies. The platform accelerates clinical trials by applying intelligent automation, predictive analytics on trial data, and generative AI for text-based documentation, reporting, and decision support in drug development.
Product overview
CiNTL.AI offers an integrated AI, ML, and GenAI platform designed specifically for the pharmaceutical and biotech industry. The platform focuses on accelerating clinical trials through intelligent automation and data analysis capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- CiNTL.AI Platform
Companies that use CiNTL
Customer profileSegments2 records
Ideal customer profiles2 records
CiNTL technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature1 record
CiNTL partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
CiNTL competitors and assessment
Company assessmentBroad incumbents
- Veeva Systems: Dominant cloud software provider for life sciences with its Veeva Vault Clinical suite covering trial management, eTMF, and CTMS. Represents the established enterprise incumbent that CiNTL must displace or integrate alongside in pharma accounts.
- Medidata (Dassault Systèmes): Industry-standard clinical trial technology platform (Rave EDC) now embedding AI/ML for protocol optimization, patient engagement, and data analytics. A scaled incumbent whose R&D and enterprise reach dwarf CiNTL's.
- IQVIA: Largest global CRO and life sciences technology vendor, embedding AI across clinical trial design, site identification, and real-world evidence. A broad incumbent competing for the same pharma AI-for-clinical-trials budget as CiNTL.
Direct peers
- TrialX: AI-driven clinical trial matching and patient recruitment platform serving pharma, biotech, and academic sponsors. Direct overlap with CiNTL's pharma/biotech customer base and clinical-trial acceleration use case.
- Median Technologies: Provides AI/ML-driven imaging biomarkers and analytics used to select and monitor patients in oncology clinical trials. Shares CiNTL's positioning of AI as a clinical-trial intelligence layer for pharma/biotech sponsors.
- Mendel: AI platform purpose-built for life sciences that structures clinical and biomedical text to support trial design, patient cohort identification, and regulatory workflows. Closely aligned with CiNTL's text-modality GenAI use cases for clinical trial documentation and analysis.
- Unlearn.AI: Applies generative AI to create digital twin patients that improve clinical trial statistical power and accelerate timelines for pharma sponsors. Shares CiNTL's positioning of AI/GenAI as a direct lever on clinical trial speed and intelligence.
- Deep 6 AI: AI platform that mines structured and unstructured clinical data to accelerate patient recruitment and trial feasibility for pharma sponsors. Directly comparable to CiNTL.AI's clinical trial acceleration focus, serving the same pharma/biotech buyer with AI-driven trial intelligence.
- Science 37: Decentralized clinical trial operating system that uses AI to enable remote patient participation and faster enrollment for pharma sponsors. Overlaps CiNTL's value proposition of accelerating clinical trials through technology-enabled intelligence.
Emerging players
- Deep Lens: AI platform for patient identification and clinical trial pre-screening, primarily serving oncology research sites and sponsors. Comparable niche focus on accelerating trial enrollment via AI, though narrower in therapeutic scope than CiNTL.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
CiNTL social profiles
Digital presenceCiNTL financial estimates
Financial estimateRevenue estimate
Valuation estimate
CiNTL leadership team
Management profileNumber of profiles
CiNTL funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CiNTL M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CiNTL
What does CiNTL do?
CiNTL.AI provides an integrated AI, ML, and GenAI platform built specifically for pharmaceutical and biotechnology companies. The platform accelerates clinical trials by applying intelligent automation, predictive analytics on trial data, and generative AI for text-based documentation, reporting, and decision support in drug development.
Is CiNTL a public or private company?
CiNTL is a private company. It is classified as unknown and is currently operating.
When was CiNTL founded?
CiNTL was founded in 2008. It employs 11 to 50 people.
Where is CiNTL based?
CiNTL is headquartered in Hilversum, Netherlands, in the Europe region.
Who are CiNTL's main competitors?
Broad incumbents on record are Veeva Systems, Medidata (Dassault Systèmes) and IQVIA. Direct peers are TrialX, Median Technologies, Mendel, Unlearn.AI, Deep 6 AI and Science 37. Deep Lens is listed as an emerging player.
Does CiNTL have an API?
No public API is recorded for CiNTL.
What industry is CiNTL in?
CiNTL's product category is Clinical Trial AI Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAEANAA, End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management). Its NAICS code is 541511 and its SIC code is 7371.